Tag: Dr. Roger M. Perlmutter
Merck to acquire OncoImmune for Covid-19 drug candidate CD24Fc
Merck acquisition of OncoImmune : Pharma giant Merck has signed an all-cash deal worth $425 million to acquire OncoImmune to gain access to the latter’s ... Read More
Merck to acquire US biopharma company VelosBio to strengthen oncology pipeline
Merck acquisition of VelosBio : US pharma giant Merck has agreed to acquire VelosBio, a California-based clinical-stage biopharma company, for $2.75 billion in an all-cash ... Read More
Seattle Genetics signs $4.4bn worth oncology deals with Merck
US biotech company Seattle Genetics has secured deals worth up to $4.4 billion with Merck, that include two new strategic oncology collaborations. The two major ... Read More
Merck to acquire coronavirus vaccine candidate developer Themis Bioscience
Merck acquisition of Themis Bioscience : Merck has signed a deal to acquire Themis Bioscience, an Austrian vaccine developer for an undisclosed price with an ... Read More
Merck acquires ArQule for $2.7bn to further diversify oncology pipeline
Merck acquisition of ArQule : Merck has completed its previously announced acquisition of ArQule for $20 per share or about $2.7 billion as per the ... Read More
Merck to acquire US biopharma company Peloton Therapeutics in $2.2bn deal
Merck acquisition of Peloton : Pharma giant Merck is set to acquire US biopharma company Peloton Therapeutics in a deal worth up to $2.2 billion, ... Read More
Merck bags EU approval for Keytruda chemo combo therapy for NSCLC
Merck has bagged the European Commission approval for the combination of its anti-PD-1 cancer immunotherapy Keytruda (pembrolizumab) with Lilly’s chemotherapy drug pemetrexed (ALIMTA) and platinum ... Read More